It seems the good times are back for Big Pharma. The sector sparked a market rally this week after several companies unveiled mergers and tie-ups worth billions.
Britain's GlaxoSmithKline revealed it would sell its cancer drugs portfolio to Swiss Novartis for around £9.5bn, while buying the Swiss firm's vaccines unit for up to £4.2bn. The two firms will also combine their consumer health business in a join venture.
Novartis is also selling its animal health business in this case, to America's Eli Lilly for $5.4bn. Canada's Valeant Pharmaceuticals made a $47bn cash and stock offer for Botox maker Allergan, supported by Allergan's biggest shareholder, activist investorBill Ackman. The news pushed Allergan's shares up by 15%, while Valeant's rose by 7.5%.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
There was also speculation that US giant Pfizer had approached London-listed AstraZeneca about a $100bn takeover which would be the biggest purchase of a UK company ever.
What the commentators said
The Swiss firm is paying seven times forecast 2014 sales and four times peak expected revenues for the unit. But it looks a smart move for GlaxoSmithKline. While looking for cancer cures is "the traditional test of virility for a big drugs group", the failure rate is extremely high.
Mega-deals are often driven by the "Napoleonic ambitions" of executives, said Leonid Bershidsky on Bloomberg View. But in pharma, they make sense. Consultancy McKinsey & Co found that of the 11 pharma groups that remained in the global Top 20 since 1995, seven had made more than $10bn-worth of acquisitions each.
On average, the deals boosted shareholder value, unlike most industries. "In a world where old cash cows are dying off, new breakthrough drugs are few and far between and time to market is longer and longer," expect the consolidation to continue.
-
How to boost your pension by £33,000 by paying it an annual Christmas bonusContributing an extra £400 into your pension pot this festive period will give the gift of compound interest and should make your retirement feel more jolly and bright
-
Japan’s medium-sized stocks provide shelter from trade warsNicholas Price, portfolio manager of Fidelity Japan Trust, tells us where to invest in Japan
